One example is represented by the treatment of breast cancer, where the administration of immunotherapy alone has not been correlated with particular clinical benefits, while immunotherapy combined with an ADC in patients with PDL-1 positive cancer subtypes resulted in a higher PFS compared to ADC in monotherapy (phase II KATE2 T-DM1 plus either atezolizumab or placebo) [85]. The gene discussed is CD274; the disease is breast carcinoma.